药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg 50 Tablets (5x10) Unit Dose boxes, Rx Only Manufactured for: AvKARE Inc. Pulaski, TN 38478 --- NDC 50268-513-15
编号:D-1045-2019登记状态:公开召回企业 / 申办者:AVKARE Inc.
登记的停止原因(原文):FDA 召回:CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 50 Tablets (5x10) Unit Dose boxes, Rx Only Manufactured for: AvKARE Inc. Pulaski, TN 38478 --- NDC 50268-514-15
编号:D-1046-2019登记状态:公开召回企业 / 申办者:AVKARE Inc.
登记的停止原因(原文):FDA 召回:CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Valsartan Tablets USP 160 mg, 100 Tablets (10 x 10) per Unit Dose Blisters, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217 (Individual Dose NDC:60687-139-11, Carton NDC#: 60687-139-01)
编号:D-1047-2019登记状态:公开召回企业 / 申办者:American Health Packaging
登记的停止原因(原文):FDA 召回:CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Losartan Potassium Tablets, USP, 25 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045 NDC 68645-577-54
编号:D-1048-2019登记状态:公开召回企业 / 申办者:Legacy Pharmaceutical Packaging LLC
登记的停止原因(原文):FDA 召回:CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-578-54
编号:D-1049-2019登记状态:公开召回企业 / 申办者:Legacy Pharmaceutical Packaging LLC
登记的停止原因(原文):FDA 召回:CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Losartan Potassium Tablets, USP, 100 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-579-54
编号:D-1050-2019登记状态:公开召回企业 / 申办者:Legacy Pharmaceutical Packaging LLC
登记的停止原因(原文):FDA 召回:CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottle (NDC: 68788-0048-03), b) 90-count bottle (NDC: 68788-0048-09), Rx Only, Mfg: Torrent Pharma Inc. Basking Ridge, NJ. Relabeled by: Preferred Pharmaceuticals, Inc. 1250 N. Lakeview Ave., Suite O, Anaheim, CA 92807.
编号:D-1051-2019登记状态:公开召回企业 / 申办者:Preferred Pharmaceuticals, Inc
登记的停止原因(原文):FDA 召回:CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ, Manufactured by: Aurolife Pharma LLC, Dayton, NJ ---- NDC 52343-122-30
编号:D-1052-2019登记状态:公开召回企业 / 申办者:Rising Pharmaceuticals, Inc.
登记的停止原因(原文):FDA 召回:CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Valsartan Tablets 80 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810 --- NDC 52343-123-90
编号:D-1053-2019登记状态:公开召回企业 / 申办者:Rising Pharmaceuticals, Inc.
登记的停止原因(原文):FDA 召回:CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2019-03-27
Valsartan Tablets 160 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810 ---- NDC 52343-124-90
编号:D-1054-2019登记状态:公开召回企业 / 申办者:Rising Pharmaceuticals, Inc.
登记的停止原因(原文):FDA 召回:CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products;安全性相关:是
查看官方原始记录 ↗